Brief Introduction

Shenzhen Lifotronic Technology Co., LTD, founded in 2008, is a national high-tech medical device innovation enterprise driven by research and development, a leading manufacturer of more than 11- premium medical devices both for diagnostic and therapeutic purposes. Stock abbreviation: PMKJ, stock code: 688389.

Headquartered in Shenzhen, China, Lifotronic operates through 4 factories and numerous sales and service subsidiaries strategically located in China. At Lifotronic, we are committed to our mission by focusing on technology innovation, quality assurance, and overall customer satisfaction.

Lifotronic is committed to becoming a respectable medical instrument and solution provider; dedicated to being a world-leading enterprise across life and time. ‘Keep developing better products and services with outstanding value for people’s health and life. Creating value for employees, shareholders, and society.’ is the mission that the whole company believes, embraces, and dedicated to, from top to bottom.

Since its establishment, Lifotronic has focused on the innovation and development of therapeutic solutions and in-vitro diagnosis products. Currently, its main business is R&D, manufacture, and sales. Lifotronic's therapeutic product line can be divided into the hospital market and homecare market according to the usage scenarios. Lifotronic's in-vitro diagnostic product line consists of the in-vitro diagnostic testing device and associated supporting reagents.

Based on the in-depth and accurate understanding of the clinical needs at all levels in the field of therapeutic and in-vitro diagnosis, Lifotronic's product strategy has focused on specialization and differentiation. Lifotronic's therapeutic product line includes eight series and more than 50 models of products;IVD product line includes four series of products and supporting reagents, both forming specialized and systematic solutions for customers and patients.

Currently, in the field of medical devices, Lifotronic has formed 8 core technologies with 80 patents. In addition, Lifotronic has built a series of systems that are mature and inter-connecting, including R&D, production and manufacturing, sales & service, and quality control management.

Having 700+ employees with 260+ R&D engineers, vast number of different product options for IVD(In-Vitro Diagnostic) and Therapy purposes, and installed Lifotronic Devices all over the world, Lifotronic is deemed as one of China’s top supplier for both diagnostic and therapeutic devices. Lifotronic has established a leading position in wound treatment, electrochemical luminescence detection, specific protein analysis, and other medical fields.

Company Overview

Full name Shenzhen Lifotronic Technology Co., Ltd.
Abbreviations Lifotronic
Code 688389
Founded Jan.16th,2008
Listing Nov.5th,2019
Domicile Shenzhen
Website www.lifotronic.com
Email lifo2008@lifotronic.com
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? No

Financials

Highlights

  2018 2017 2016
Earnings Per Share 0.21 0.13  
R&D expenditure as a % of operating revenue 20.61% 19.92% 22.60%
Operating Revenue 323.43 250.83 174.54
Net Income 81.14 47.59 9.88

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 323.43 250.83 174.54
Operating Costs 130.76 97.87 69.21
Operating Income 89.65 54.41 -11.20
Pretax Income 89.67 54.46 11.67
Income Tax 8.53 6.87 1.79
Net Income 81.14 47.59 9.88

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Assets
Current Assets-Total 582.93 549.32 441.93
Non-current Assets-Total 229.00 161.07 555.88
Total Assets 811.93 710.40 497.52
Liabilities
Current Liabilities-Total 107.84 76.49 67.06
Non-current Liabilities-Total 35.69 46.65 59.63
Total Liabilities 143.53 123.15 126.69
Stockholder's Equity
Share Capital 565.97 565.97 320.05
Retained Profits 102.42 21.28 50.78
Minority Interests - - -
Total Owners' Equity 668.39 587.25 370.82

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 81.14 35.25 28.00
Net Cash Flows-Investing -58.21 -111.43 -27.58
Net Cash Flows-Financing -3.37 162.66 205.68

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
刘先成 12,235.36 28.98%
深圳瀚钰生物科技合伙企业(有限合伙) 3,416.94 8.09%
深圳瑞源成健康产业投资管理中心(有限合伙) 2,945.88 6.98%
深圳瑞普医疗技术研究所(有限合伙) 2,883.67 6.83%
曾映 1,881.29 4.46%
胡明龙 1,881.29 4.46%
张海英 1,393.56 3.30%
徐岩 1,254.20 2.97%
深圳市创新投资集团有限公司 1,122.90 2.66%
北京华泰瑞合医疗产业投资中心(有限合伙) 1,102.39 2.61%
(Date of filling:Nov.20th, 2019)

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.